Advisory Services Network LLC Boosts Stock Position in Danaher Co. (NYSE:DHR)

Advisory Services Network LLC boosted its position in Danaher Co. (NYSE:DHRFree Report) by 0.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,138 shares of the conglomerate’s stock after buying an additional 55 shares during the period. Advisory Services Network LLC’s holdings in Danaher were worth $4,529,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC increased its holdings in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. BKM Wealth Management LLC acquired a new position in shares of Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher during the 4th quarter worth approximately $29,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Danaher during the first quarter worth $30,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR traded up $1.59 during mid-day trading on Friday, reaching $247.86. 508,232 shares of the company’s stock were exchanged, compared to its average volume of 2,843,939. The business’s fifty day simple moving average is $255.05 and its 200-day simple moving average is $247.31. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $269.11. The stock has a market capitalization of $183.59 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 3.70 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the prior year, the business earned $2.36 EPS. The firm’s revenue was down 2.6% compared to the same quarter last year. On average, equities research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DHR. Citigroup upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Robert W. Baird lifted their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Finally, Bank of America upped their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $268.67.

Check Out Our Latest Stock Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.